A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1

Vaccine

Volumn 29, Issue 44, 2011, Pages 7811-7817

  Tetteh, Kevin K A ^a   Conway, David J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antigenic polymorphism; Malaria vaccine; Merozoite; Plasmodium falciparum

Indexed keywords

ANTIBODY; HYBRID PROTEIN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1;

ALLELISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ESCHERICHIA COLI; EVALUATION; IMMUNOGENICITY; INVERTED REPEAT; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT;

ANIMALS; ANTIBODIES, PROTOZOAN; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; MICE; PLASMODIUM FALCIPARUM; RABBITS; RECOMBINANT FUSION PROTEINS;

EID: 80053581943     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.106     Document Type: Article

References (44)

1. Enosse S., Dobano C., Quelhas D., Aponte J.J., Lievens M., Leach A., et al. RTS,S/ASO2A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials 2006, 1:e5.
2. Weedall G.D., Conway D.J. Detecting signatures of balancing selection to identify targets of anti-parasite immunity. Trends Parasitol 2010, 26:363-369.
3. Takala S.L., Coulibaly D., Thera M.A., Batchelor A.H., Cummings M.P., Escalante A.A., et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 2009, 1:2ra5.
4. Bannister L.H., Mitchell G.H. The malaria merozoite, forty years on. Parasitology 2009, 136:1435-1444.
5. Child M.A., Epp C., Bujard H., Blackman M.J. Regulated maturation of malaria merozoite surface protein-1 is essential for parasite growth. Mol Microbiol 2010, 78:187-202.
6. Woehlbier U., Epp C., Hackett F., Blackman M.J., Bujard H. Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion. Malar J 2010, 9:77.
7. Gilson P.R., O'Donnell R.A., Nebl T., Sanders P.R., Wickham M.E., McElwain T.F., et al. MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Mol Microbiol 2008, 68:124-138.
8. de Koning-Ward T.F., O'Donnell R.A., Drew D.R., Thomson R., Speed T.P., Crabb B.S. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med 2003, 198:869-875.
9. O'Donnell R.A., Saul A., Cowman A.F., Crabb B.S. Functional conservation of the malaria vaccine antigen MSP1-19across distantly related Plasmodium species. Nat Med 2000, 6:91-95.
10. Holder A.A. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 2009, 136:1445-1456.
11. Polley S.D., Tetteh K.K., Cavanagh D.R., Pearce R.J., Lloyd J.M., Bojang K.A., et al. Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect Immun 2003, 71:1833-1842.
12. Conway D.J., Cavanagh D.R., Tanabe K., Roper C., Mikes Z.S., Sakihama N., et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 2000, 6:689-692.
13. Galamo C.D., Jafarshad A., Blanc C., Druilhe P. Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition. J Infect Dis 2009, 199:1151-1154.
14. Cavanagh D.R., Dodoo D., Hviid L., Kurtzhals J.A., Theander T.G., Akanmori B.D., et al. Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun 2004, 72:6492-6502.
15. Tetteh K.K., Cavanagh D.R., Corran P., Musonda R., McBride J.S., Conway D.J. Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen. Infect Immun 2005, 73:5928-5935.
16. Miller L.H., Roberts T., Shahabuddin M., McCutchan T.F. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 1993, 59:1-14.
17. Takala S.L., Escalante A.A., Branch O.H., Kariuki S., Biswas S., Chaiyaroj S.C., et al. Genetic diversity in the Block 2 region of the merozoite surface protein 1 (MSP-1) of Plasmodium falciparum: additional complexity and selection and convergence in fragment size polymorphism. Infect Genet Evol 2006, 6:417-424.
18. Noranate N., Prugnolle F., Jouin H., Tall A., Marrama L., Sokhna C., et al. Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic setting. BMC Microbiol 2009, 9:219.
19. Osier F.H., Fegan G., Polley S.D., Murungi L., Verra F., Tetteh K.K., et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008, 76:2240-2248.
20. Locher C.P., Tam L.Q., Chang S.P., McBride J.S., Siddiqui W.A. Plasmodium falciparum: gp195 tripeptide repeat-specific monoclonal antibody inhibits parasite growth in vitro. Exp Parasitol 1996, 84:74-83.
21. Parra M., Hui G., Johnson A.H., Berzofsky J.A., Roberts T., Quakyi I.A., et al. Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1. Infect Immun 2000, 68:2685-2691.
22. Harris P.K., Yeoh S., Dluzewski A.R., O'Donnell R.A., Withers-Martinez C., Hackett F., et al. Molecular identification of a malaria merozoite surface sheddase. PLoS Pathog 2005, 1:241-251.
23. Kimbi H.K., Tetteh K.K., Polley S.D., Conway D.J. Cross-sectional study of specific antibodies to a polymorphic Plasmodium falciparum antigen and of parasite antigen genotypes in school children on the slope of Mount Cameroon. Trans R Soc Trop Med Hyg 2004, 98:284-289.
24. Cavanagh D.R., McBride J.S. Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1. Mol Biochem Parasitol 1997, 85:197-211.
25. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002, 185:820-827.
26. Fluck C., Schopflin S., Smith T., Genton B., Alpers M.P., Beck H.P., et al. Effect of the malaria vaccine combination B on merozoite surface antigen 2 diversity. Infect Genet Evol 2007, 7:44-51.
27. Faber B.W., Remarque E.J., Morgan W.D., Kocken C.H., Holder A.A., Thomas A.W. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect Immun 2007, 75:5947-5955.
28. Malkin E., Hu J., Li Z., Chen Z., Bi X., Reed Z., et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008, 26:6864-6873.
29. Mazumdar S., Mukherjee P., Yazdani S.S., Jain S.K., Mohmmed A., Chauhan V.S. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response. Infect Immun 2010, 78:872-883.
30. Remarque E.J., Faber B.W., Kocken C.H., Thomas A.W. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 2008, 76:2660-2670.
31. Kusi K.A., Faber B.W., Riasat V., Thomas A.W., Kocken C.H., Remarque E.J. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS ONE 2010, 5:e15391.
32. Kennedy M.C., Wang J., Zhang Y., Miles A.P., Chitsaz F., Saul A., et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 2002, 70:6948-6960.
33. Biswas S., Dicks M.D., Long C.A., Remarque E.J., Siani L., Colloca S., et al. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS ONE 2011, 6:e20977.
34. Quakyi I.A., Taylor D.W., Johnson A.H., Allotey J.B., Berzofsky J.A., Miller L.H., et al. Development of a malaria T-cell vaccine for blood stage immunity. Scand J Immunol Suppl 1992, 11:9-16.
35. Comoy E.E., Capron A., Thyphronitis G. In vivo induction of type 1 and 2 immune responses against protein antigens. Int Immunol 1997, 9:523-531.
36. Daly T.M., Long C.A. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Infect Immun 1996, 64:2602-2608.
37. Douglas A.D., de Cassan S.C., Dicks M.D., Gilbert S.C., Hill A.V., Draper S.J. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 2010, 28:7167-7178.
38. Crompton P.D., Miura K., Traore B., Kayentao K., Ongoiba A., Weiss G., et al. In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun 2010, 78:737-745.
39. Cavanagh D.R., Dubois P.M., Holtel A., Kisser A., Leroy O., Locke E., et al. Towards validated assays for key immunological outcomes in malaria vaccine development. Vaccine 2011, 29:3093-3095.
40. Boyle M.J., Wilson D.W., Richards J.S., Riglar D.T., Tetteh K.K., Conway D.J., et al. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci USA 2010, 107:14378-14383.
41. Jones T.R., Narum D.L., Gozalo A.S., Aguiar J., Fuhrmann S.R., Liang H., et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 Region II DNA prime-protein boost immunozation regimen. J Infect Dis 2001, 183:303-312.
42. Hisaeda H., Saul A., Reece J.J., Kennedy M.C., Long C.A., Miller L.H., et al. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 2002, 185:657-664.
43. Stowers A.W., Cioce V., Shimp R.L., Lawson M., Hui G., Muratova O., et al. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun 2001, 69:1536-1546.
44. Dutta S., Sullivan J.S., Grady K.K., Haynes J.D., Komisar J., Batchelor A.H., et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 2009, 4:e8138.